Labopharm Inc. has announced its analgesic Tramadol, which is in late-stage trials, was found to be a safe alternative for the management of pain.
In a statement, the drugmaker said Tramadol has received regulatory approval in 22 European countries and Mexico and commercial launch of the product across Europe is underway.
For the U.S. market, Labopharm has secured a licensing and distribution agreement with Purdue Pharma.
Tramadol is classified as an mild opiate drug.
Tramadol is a racemic mixture of 2 enantiomers (mirror images of each other), each one displaying differing affinities for various receptors. Tramadol is a selective agonist of mu receptors and preferentially inhibits serotonin reuptake, whereas (-)-tramadol mainly inhibits noradrenaline reuptake. The action of these 2 enantiomers is both complementary and synergistic and results in the analgesic effect. Very interesting mechanism of action.
Labopharm is publically traded under the symbol DDS.TO on the Toronto Exchange.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment